Economic Evaluation of First-Line Adjuvant Chemotherapies for Resectable Gastric Cancer Patients in China
Figure 3
Base-case results on the cost-effectiveness of first-line strategies for resectable gastric cancer patients.
The line joining strategies of capecitabine and oxaliplatin (XELOX) and S-1 is the ‘efficiency frontier’. Strategy above the line is dominated. In the cost-effectiveness plane, the value of incremental cost-effectiveness ratios (ICER) is depicted.